Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Nrc Health (NRC) Shares Outstanding (Diluted Average) (2016 - 2026)

Nrc Health's Shares Outstanding (Diluted Average) history spans 16 years, with the latest figure at $22.4 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) fell 5.67% to $22.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $22.4 million, a 5.67% decrease, with the full-year FY2025 number at $22.4 million, down 5.67% from a year prior.
  • Shares Outstanding (Diluted Average) hit $22.4 million in Q4 2025 for Nrc Health, up from $22.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for NRC hit a ceiling of $25.7 million in Q1 2021 and a floor of $22.1 million in Q3 2025.
  • Historically, Shares Outstanding (Diluted Average) has averaged $24.4 million across 5 years, with a median of $24.7 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): fell 0.21% in 2021 and later fell 7.28% in 2025.
  • Tracing NRC's Shares Outstanding (Diluted Average) over 5 years: stood at $25.6 million in 2021, then fell by 2.29% to $25.1 million in 2022, then fell by 1.51% to $24.7 million in 2023, then fell by 3.77% to $23.7 million in 2024, then decreased by 5.67% to $22.4 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for NRC at $22.4 million in Q4 2025, $22.1 million in Q3 2025, and $22.7 million in Q2 2025.